Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Exelixis on the precipice for approval in Europe
Company: Ipsen (OTCPK:IPSEY) and Exelixis (EXEL)
Therapy: Cabozantinib
Disease: Intermediate- or poor-risk renal cell (kidney) cancer
News: IPSEY announced that the CHMP has granted a positive opinion for the first-line use of cabozantinib in advanced kidney